Add a Comment By Maureen Salamon, BA  |  Thursday, August 22, 2013 An international study led by Memorial Sloan-Kettering found that pazopanib (Votrient ® ) controls cancer as effectively as sunitinib (Sutent ® ) while improving patients’ quality of life. read more

View article:
Comparison of Drugs for Advanced Kidney Cancer Suggests Side Effects Are More Manageable with Newer Option

Scroll to Top